Abstract Background: Complex regional pain syndrome is characterized by severe, persistent pain. Emerging evidence suggests that cannabis‐based medicinal products may…
Abstract Background: A third of epilepsy patients fail to enter seizure remission despite optimal therapeutic management. Cannabis‐based medicinal products (CBMPs)…
Abstract Objective: The study aims to evaluate the clinical outcomes in patients with hypermobility spectrum disorder (HSD) and hypermobile Ehlers–Danlos…
Abstract Introduction: Chronic pain (CP) affects 35.0%–51.3% of the UK population, with 67%–88% reporting sleep disturbances. Cannabis‐based medicinal products (CBMPs)…
Abstract The aim of this study was to assess changes in validated patient-reported outcome measures after initiation of cannabis-based medicinal…
Abstract Introduction: The primary aim of this study was to assess changes in sleep‐specific health‐related quality of life (HRQoL) for…
Abstract This study aims to analyze changes in health-related quality of life (HRQoL) and safety in patients with generalized anxiety…
Abstract Background: Research on cannabis‐based medicinal products (CBMPs) in anxiety remains inconclusive due to a paucity of high‐quality evidence. Studies…
Abstract Aim: This study aims to analyze the health‐related quality of life (HRQoL) and safety outcomes in attention‐deficit/hyperactivity disorder (ADHD)…
Abstract Introduction: While there is increasing evidence of the effects of cannabis‐based medicinal products (CBMPs) on health‐related quality of life…